(08-07-2021, 07:03 AM)ken-do-nim Wrote:I have owned this flying turkey for 27 years lol. I doubled down on early vaccine news and gradually trimming back the past few months. A little early of course but a nice profit on PFE and I am not used to that lol. When the delta surge starts pulling back PFE could be expected to pull back some. The small companies involved in this were the big scores. They are also tough to value once the Covid subsides. I know you like Moderna. I agree they have a future. What's it actually worth today, or a year from now? I have no clue.(08-07-2021, 06:33 AM)fenders53 Wrote: I would be cautious chasing PFE with much money here. Sure their revenues will be amazing for 2021/22 but it's a hard act to follow. Maybe these vaccine makers do have room to go higher but some quarter soon the phase 3 stable will be what matters to the market. PFE is not a biotech startup that runs higher on phase one hopes.
This article agrees with you.
While I believe the messenger RNA vaccines will change biotech forever, the article did note that in some people it causes heart inflammation.
I will probably lead with a starter position on it (which has moved up to $3k).
And any vaccine will have side effects. How virulent the disease is plays a part. I don't want small pox. A normal flu strain won't likely harm a 30 yr old so they vaxx better be VERY unlikely to cause an issue which requires years of testing. The very reason some won't get vaxxed now when they clearly should.
COMP sales will haunt some companies. When 2022 comes and your revenues are about the same as 2020, you better have a good future story to sell or a high PE comes under scrutiny in a market that is less bubbly. Nothing seems to matter today so enjoy it while we can. Right or wrong, it is why I trim things that get out of hand.